Hossein Borghaei, DO, on Nonsquamous NSCLC: Findings on Sitravatinib Plus Nivolumab vs Docetaxel

November 01, 2023 By The ASCO Post Staff

Hossein Borghaei, DO, of Fox Chase Cancer Center, discusses phase III findings from the SAPPHIRE study of sitravatinib plus nivolumab vs docetaxel in patients with previously treated, advanced nonsquamous non–small cell lung cancer (NSCLC) (Abstract LBA63).

Related Content